ASCO 2023 | ACE-536-MF-001 update: luspatercept for the treatment of anemia in myelofibrosis
Aaron Gerds, MD, Cleveland Clinic Taussig Cancer Center, Cleveland, OH, gives an update on the Phase II ACE-536-MF-001 trial (NCT03194542) findings, assessing the safety and efficacy of luspatercept in patients with myelofibrosis (MF)-related anemia. The trial included four cohorts categorized by transfusion dependence and ruxolitinib treatment. Results demonstrated that luspatercept can be safely combined with ruxolitinib, demonstrating minimal toxicity. Notably, positive treatment response was observed across all groups, with the highest response seen in transfusion-dependent patients receiving ruxolitinib. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
